Pharmacology Watch – May 1, 2016
May 1, 2016
View Issues
-
Federal Agencies, States Move Swiftly to Combat Opioid Overdose Epidemic
CDC issues new pain management guidelines; White House, states bring own ideas to the table.
-
More Evidence Supports Timing Hypothesis for Hormone Therapy
More evidence that supports the timing hypothesis (or the critical window-of-opportunity hypothesis) for hormone therapy to slow atherosclerosis progression.
-
New Guidelines for Dual Antiplatelet Therapy
The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event.
-
FDA Actions
In this section: boxed warning to all immediate-release opioids; eased restrictions on mifepristone used with misoprostol used for medical abortions; reslizumab for the maintenance treatment of severe asthma; and ixekizumab for the treatment of adults with moderate-to-severe plaque psoriasis.